Drug Discovery World

JULY 22, 2022

As a result, researchers are striving to continually improve immuno-oncology approaches using the patient’s own immune cells to combat tumours. Going beyond the limits of immune checkpoint inhibitors (ICIs). However, adverse effects such as cytokine release syndrome (CRS) and neurotoxicity still occur.

In-Vivo 52

In-Vivo Engineer In-Vitro Medicine 52

Drug Discovery World

FEBRUARY 15, 2023

Cancer is a complex heterogenous multistep disease characterised by uncontrolled cell proliferation combined with a dysregulated immune response. A healthy immune system is naturally primed to eliminate malignant and abnormal cells through a synchronised and dynamic interplay between adaptive and innate immunity.

Research 52

Research In-Vitro In-Vivo Development 52

Drug Discovery World

NOVEMBER 8, 2023

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting. Antibody drug conjugates (ADCs) This session will include three presentations, two clinical updates, two poster highlights, and two luncheon presentations.

Antibody 64

Antibody Engineer Protein Scientist 64